Augmenting Flortaucipir Dosimetry Estimates
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02336360|
Recruitment Status : Completed
First Posted : January 13, 2015
Results First Posted : August 11, 2020
Last Update Posted : August 11, 2020
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: Flortaucipir F18||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451|
|Study Start Date :||January 2015|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||June 2015|
Experimental: Urine Analysis
Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.
Drug: Flortaucipir F18
No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.
- Urine Analysis - Total Integrated Radioactivity Excreted in Urine [ Time Frame: 0-360 minutes post injection ]Total integrated radioactivity excreted in urine over time will be determined to augment previous radiation dosimetry calculations.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02336360
|United States, Connecticut|
|New Haven, Connecticut, United States, 06510|